Inhibition of platelet-activating factor (PAF)-induced platelet aggregation by fatty acids from human saliva

References

• Hanahan DJ. Platelet-activating factor: a biologically active phosphoglyceride. Ann Rev Biochem. 1986; 55: 483–509. 10.1146/annurev.bi.55.070186.002411
   PubMed Web of Science ®Google Scholar
• Wykle RL, O’Flaherty JT, Thomas MJ. Platelet-activating factor. Methods Enzymol. 1988; 163: 44–54.
   PubMed Web of Science ®Google Scholar
• Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Progress Lipid Res. 2000; 39: 41–82.
   PubMed Web of Science ®Google Scholar
• Deng M, Guo H, Tam JW, Johnson BM, Brickey WJ, New JS, Lenox A, Shi H, Golenbock DT, Koller BH. et al. Platelet-activating factor (PAF) mediates NLRP3-NEK7 inflammasone induction independently of PAFR. J Exp Med. 2019; 216: 2838–2853. 10.1084/jem.20190111
   PubMedGoogle Scholar
• Lordan R, Tsoupras A, Zabetakis I, Demopoulos CA. Forty years since the structural elucidation of platelet-activating factor (PAF); Historical, current, and future research perspectives. Molecules. 2019. 24: 4414. 10.3390/molecules24234414
   Google Scholar
• Hanahan DJ, Weintraub ST. Platelet-activating factor; isolation, identification, and assay. Methods Biochem Anal. 1985; 31: 195–219.
   PubMedGoogle Scholar
• Smal MA, Baldo BA, McCaskill A. A specific sensitive radioimmunoassay for platelet-activating factor (PAF). J Immunol Methods. 1990; 128: 183–188. 10.1016/0022-1759(90)90209-E
   PubMedGoogle Scholar
• Cooney SJ, Smal MA, Baldo BA. Quantitation by radioimmunoassay of PAF in human saliva. Lipids. 1991; 26: 1140–1143. 10.1007/BF02536518
   PubMedGoogle Scholar
• Cooney SJ, Smal MA, Baldo BA. Stability of platelet activating factor (PAF) in human saliva. Clin Chim Acta. 1991; 200: 161–174. 10.1016/0009-8981(91)90087-S
   PubMedGoogle Scholar
• Cooney SJ, Smal MA, Baldo BA. Measurement of PAF in blood by radioimmunoassay. Examination of interfering factors and problems involved in accurate quantification. J Immunol Methods. 1992; 151: 131–138. 10.1016/0022-1759(92)90111-6
   PubMed Web of Science ®Google Scholar
• Cox CP, Wardlow ML, Jorgensen R, Farr RS. The presence of platelet-activating factor (PAF) in normal human mixed saliva. J Immunol. 1981; 127: 46–50.
   PubMed Web of Science ®Google Scholar
• Janero DR, Burghardt B, Burghardt C. Radioligand competitive binding methodology for the evaluation of platelet-activating factor (PAF) and PAF-receptor antagonism using intact canine platelets. J Pharmacol Methods. 198820: 237–253.
   Google Scholar
• Smal MA, Baldo BA. Inhibitor(s) of platelet-activating factor (PAF) in human saliva. Lipids. 1991; 26: 1144–1147. 10.1007/BF02536519
   PubMedGoogle Scholar
• Pinckard RN, Farr RS, Hanahan DJ. Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from sensitized basophils. J Immunol. 1979; 123: 1847–1857.
   PubMed Web of Science ®Google Scholar
• Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37: 911–917. 10.1139/o59-099
   PubMedGoogle Scholar
• Longenecker GL. Platelet arachidonic acid metabolism. Longenecker GL, editor. The platelets: physiology and pharmacology. New York: Academic Press. 1985. 159–185.
   Google Scholar
• Slomiany BL, Zdebska E, Murty VL, Slomiany A, Petropoulou K, Mandel ID. Lipid composition of human labial salivary gland secretions. Arch Oral Biol. 1983; 28: 711–714. 10.1016/0003-9969(83)90105-X
   PubMedGoogle Scholar
• Mandel ID, Eisenstein A. Lipids in human salivary secretions and salivary calculus. Arch Oral Biol. 1969; 14: 231–233. 10.1016/0003-9969(69)90067-3
   PubMed Web of Science ®Google Scholar
• Slomiany BL, Aono M, Murty VL, Slomiany A, Levine MJ, Tabak LA. Lipid composition of submandibular saliva from normal and cystic fibrosis individuals. J Dental Res. 1982; 61: 1163–1166. 10.1177/00220345820610101001
   PubMedGoogle Scholar
• Kitagawa S, Endo J, Kametani F. Effects of long-chain cis-unsaturated fatty acids and their alcohol analogs on aggregation of bovine platelets and their relation with membrane fluidity change. Biochim Biophys Acta. 1985; 818: 391–397. 10.1016/0005-2736(85)90014-8
   PubMedGoogle Scholar
• MacIntyre DE, Hoover RL, Smith M, Steer M, Lynch C, Karnovsky MJ, Salzman EW. Inhibition of platelet function by cis-unsaturated fatty acids. Blood. 1984; 63: 848–857. 10.1182/blood.V63.4.848.848
   PubMedGoogle Scholar
• Croset M, Lagarde M. In vitro incorporation and metabolism of icosapentaenoic acid docosahexaenoic acids in human platelets – effect in aggregation. Thromb Haemost. 1986; 56: 57–62. 10.1055/s-0038-1661603
   PubMed Web of Science ®Google Scholar
• Srivastava KC. Docosahexaenoic acid (C22:6 omega 3) and linoleic acid are anti-aggregatory, and alter arachidonic acid metabolism in human platelets. Prostaglandins Leukot Med. 1985; 17: 319–327. 10.1016/0262-1746(85)90121-0
   PubMedGoogle Scholar
• Dratewska-Kos E, Tinker DO, Kindi B. Unsaturated fatty acids inhibit ADP-arachidonate-induced platelet aggregation without affecting thromboxane synthesis. Biochem Cell Biol. 1986; 64: 906–913. 10.1139/o86-121
   PubMedGoogle Scholar
• Sato T, Nakao K, Hashizume T, Fujii T. Inhibition of platelet aggregation by unsaturated fatty acids through interference with thromboxane-mediated process. Biochim Biophys Acta. 1987; 931: 157–164. 10.1016/0167-4889(87)90201-1
   PubMedGoogle Scholar
• Siess W. Molecular mechanisms of platelet-activation. Physiol Rev. 1989; 69: 58–178. 10.1152/physrev.1989.69.1.58
   PubMed Web of Science ®Google Scholar
• Nakayama R, Yasuda K, Saito K. Existence of endogenous inhibitors of platelet-activating factor (PAF) with PAF in rat uterus. J Biol Chem. 1987; 262: 13174–13179. 10.1016/S0021-9258(18)45184-8
   PubMedGoogle Scholar
• Lekka M, Tokumura A, Tsuji H, Hanahan DJ. Isolation of a phospholipid inhibitor of platelet activating factor-induced activity from perfused rat liver: identification as phosphatidylglycerol. Arch Biochem Biophys. 1993; 302: 380–384. 10.1006/abbi.1993.1227
   PubMedGoogle Scholar
• Woodard DS, Ostrom K, McManus LM. Lipid inhibitors of platelet-activating factor (PAF) in normal human plasma. J Lipid Mediat Cell Signal. 1995; 12: 11–28. 10.1016/0929-7855(95)00004-A
   PubMedGoogle Scholar
• Masugi F, Ogihara T, Saeki S, Sakaguchi K, Kumahara Y, Satouchi K, Oda M, Saito K, Tokunaga K. Endogenous platelet-activating factor and anti-platelet-activating factor in patients with renovascular hypertension. Life Sci. 1988; 42: 455–460. 10.1016/0024-3205(88)90084-7
   PubMedGoogle Scholar
• Macpherson JL, Kemp A, Rogers M, Mallet AI, Toia RF, Spur B, Earl JW, Chesterman CN, Krilis SA. Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. Clin Exp Immunol. 1989; 77: 391–396.
   PubMed Web of Science ®Google Scholar
• Miwa M, Hill C, Kumar R, Sugatani J, Olson MS, Hanahan DJ. Occurrence of an endogenous inhibitor of platelet-activating factor in rat liver. J Biol Chem. 1987; 262: 527–530. 10.1016/S0021-9258(19)75812-8
   PubMedGoogle Scholar
• Siafaka-Kapadai A, Hanahan DJ. An endogenous inhibitor of PAF-induced platelet aggregation, isolated from rat liver, has been identified as free fatty acid. Biochim Biophys Acta. 1993; 1166: 217–221. 10.1016/0005-2760(93)90100-N
   PubMedGoogle Scholar
• Nunez D, Randon J, Gandhi C, Siafaka-Kapadai A, Olson MS, Hanahan DJ. The inhibition of platelet-activating factor-induced platelet activation by oleic acid is associated with a decrease in polyphosphoinositide metabolism. J Biol Chem. 1990; 265: 18330–18338. 10.1016/S0021-9258(17)44756-9
   PubMedGoogle Scholar
• Kimoto M, Javors MA, Ekholm J, Siafaka-Kapadai A, Hanahan DJ. Dual effects of oleic acid in Ca2+ mobilization and protein phosphorylation in human platelets in presence or absence of platelet activating factor. Arch Biochem Biophys. 1992; 298: 471–479. 10.1016/0003-9861(92)90437-2
   PubMedGoogle Scholar
• Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JP. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. The Lancet. 1978; 3128081: 117–119. 10.1016/S0140-6736(78)91505-2
   Google Scholar
• Gil Á. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother. 2002; 56: 388–396. 10.1016/S0753-3322(02)00256-1
   PubMed Web of Science ®Google Scholar
• Calder PC. n-3 Polyunsaturated fatty acids, inflammation and inflammatory diseases. Am J Clin Nutr. 2006; 83Suppl: 1505S–1519S. 10.1093/ajcn/83.6.1505S
   PubMed Web of Science ®Google Scholar
• Marion-Letellier R, Savoye G, Ghosh S. Polyunsaturated fatty acids and inflammation. Int Union Biochem Mol Biol. 2015; 67: 659–667. 10.1002/iub.1428
   Google Scholar
• Michalak A, Mosińska P, Fichna J. Polyunsaturated fatty acids and their derivatives. Therapeutic value for inflammatory, functional gastrointestinal disorders, and colorectal cancer. Front Pharmacol. 2016. 7: 459. 10.3389/fphar.2016.00459
   PubMedGoogle Scholar
• Zimmerman GA, McIntyre TM, Prescott SM, Stafforini NM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002; 30: S294–S301. 10.1097/00003246-200205001-00020
   PubMed Web of Science ®Google Scholar
• McManus LM, Pinckard RN. PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med. 2000; 11: 240–258. 10.1177/10454411000110020701
   PubMedGoogle Scholar
• Ribaldi E, Guerra M, Mezzasoma AM, Staffolani N, Goracci G, Gresele P. PAF levels in saliva are regulated by inflammatory cells. J Peridontal Res. 1998; 33: 237–241. 10.1111/j.1600-0765.1998.tb02195.x
   PubMedGoogle Scholar